This invention pertains to methods and devices for delivering therapy to the heart with electrical stimulation.
Cardiac rhythm management devices are implantable battery-powered devices that provide electrical stimulation to selected chambers of the heart in order to treat disorders of cardiac rhythm. A pacemaker, for example, is a cardiac rhythm management device that paces the heart with timed pacing pulses. The most common condition for which pacemakers have been used is in the treatment of bradycardia, where the ventricular rate is too slow. If functioning properly, the pacemaker makes up for the heart's inability to pace itself at an appropriate rhythm in order to meet metabolic demand by enforcing a minimum heart rate and/or artificially restoring AV conduction. Implantable devices may also be configured to treat tachyarrhythmias such as tachycardia and fibrillation with electrical stimulation. An implantable cardioverter/defibrillator (ICD) provides this kind of therapy by delivering a shock pulse to the heart when the device detects fibrillation. Another type of electrical therapy for tachyarrhythmias is anti-tachycardia pacing (ATP). In ATP, the heart is competitively paced with one or more pacing pulses in an effort to interrupt the reentrant circuit causing a tachycardia. ATP can be applied to either the ventricles or the atria. Modern ICD's typically are also pacemakers with ATP capability configured so that ATP therapy is delivered to the heart when a tachycardia is detected, while a shock pulse is delivered when fibrillation occurs.
The delivery of pacing pulses to heart, whether to treat bradycardia or tachycardia, is a transfer of energy that can have deleterious physiological effects if sustained over a long enough period and at a high enough rate. In order to prevent this possibility, it would be desirable for a pacemaker to be configured to monitor the rate at which pacing energy is transferred as well as the cumulative amount of the energy as the pacemaker delivers pacing therapy in different modes.
A pacing monitoring system is described for incorporation in an implantable pacemaker that monitors the pacing rate and/or cumulative pace count in order to protect a patient from excessive pacing. The system includes monitoring circuitry that is configured to operate in multiple monitoring zones, where each zone is adapted to prevent excessively high-rate pacing during a particular mode of device operation.
The normal decision on the rate for energy delivery in an implantable pacemaker delivering bradycardia pacing is a complex combination based on the target rate programmed by the patient's physician, detected activity level of the patient, and the current pacing mode of the device. In addition, ATP therapies to treat fast heart rates involve short bursts of rapid pacing into either the atrium or ventricle (depending on where the fast heart rate is detected). Pacemakers may also be configured with other high-rate pacing modes that enable an electro-physiologist to test the patient for certain heart conditions. Although a pacemaker could be configured to simply always limit the pacing rate below a level considered unsafe, any of the types of pacemaker operation just mentioned may require temporary pacing at rates that would be hazardous if sustained for long periods. Simply disabling protection against excessive pacing during such therapy delivery is not a desirable option since that would leave the patient vulnerable to excessively high-rate pacing as a result of erroneous device behavior.
Disclosed herein is a pacemaker that incorporates an adaptable pacing rate monitor to protect the patient from erroneous high-rate pacing. The pacing rate monitor utilizes separate protection zones for different classes of pacing therapy. Such a multiple zone approach adapts the pacing rate protection to the type of therapy being delivered by providing separate protection zones for pacing modes that deliver energy at different rates. The criteria for acceptable pace delivery in each zone are tailored to the therapy requirements for that zone, maximizing the probability of detection of erroneous device behavior. For example, separate zones for high rate pacing into both the atrium and ventricle may be provided, as the hazards associated with each are different. Patient safety is thereby maintained in the presence of device failures while still allowing for delivery of the desired therapy.
In an exemplary embodiment, the pacing rate monitor is capable of operating in four monitoring zones: a normal-rate zone, a high-rate zone, an unlimited-rate zone, and a fail-safe zone. During normal bradycardia pacing, the monitor operates in the normal-rate zone, where a single pacing rate limit is set for both the atrium and ventricles based on a clinically acceptable maximum sustained pacing rate. A pace scheduled to be delivered by the pacing circuitry is blocked if that pace would result in a pacing rate above the pacing rate limit. In addition, a grace interval may be provided to allow a second pace to occur very soon after a first pace, while the heart tissue would be in refractory, even if the pace would occur at an interval after the first pace that would violate the pacing rate limit. No hazard exists if the second pace is delivered into refractory tissue which will not respond to further stimulation. Closely spaced back-up pacing is used in some normal operating modes to ensure capture by a pacing pulse (e.g., auto capture paces and safety paces) and are not blocked in this embodiment. Any additional pace that occurs after the grace interval and exceeds the set high-rate limit, however, will be blocked and an error declared. While the device is delivering ATP therapy in this embodiment, the monitor operates in a high-rate zone that allows a higher pacing rate than the normal-rate zone and also enforces a pace count limit that limits the cumulative number of paces delivered over a specified period time. A high-rate zone may also be useful for performing certain diagnostic testing procedures with pacing stimulation.
Separate atrial and ventricular high-rate zones may be provided for delivering atrial or ventricular ATP therapy so that a higher rate burst of paces is permitted into either the atrium or ventricle while the other chamber is kept in the normal-rate zone. Each high-rate zone may have its own pacing rate limit. For example, the ventricular high-rate zone may allow pacing rates of up to 500 pulses per minute, while the atrial high-rate zone may allow pacing up to 1500 pulses per minute. The grace interval for closely spaced pacing remains operative for the chamber receiving pacing monitored in the normal-rate zone, while no grace interval is used in monitoring the chamber where high-rate delivery is allowed in high-rate zone. The maximum number of paces allowed while in either of these high-rate zones is limited to a specified maximum count limit. Any pace that exceeds the set high-rate limits or exceeds the count limit will be blocked and an error declared. Separate atrial and ventricular high-rate monitoring zones allow a pacemaker to deliver atrial ATP therapy without creating the risk of fast pacing into the ventricle which could trigger ventricular fibrillation. Fast ventricular pacing is required for ventricular ATP and is usually only provided in devices with a high-voltage defibrillator to protect against fatal fast rhythms.
Also in an exemplary embodiment, the pacing monitor may be made to operate in an unlimited-rate zone where no pacing rate limits or pace count limits are enforced. The unlimited-rate zone is useful for certain tests performed under the supervision of an electro-physiologist. In this zone, pacing is limited to a time period (e.g., 2 seconds) after which an error is declared. The time-limit of the unlimited-rate zone may be configured to be restarted a specified maximum number of times by a manually input (i.e., via a telemetry) signal. A fail-safe zone is activated in response to a system-reset or an error in any of the other monitor zones. The fail-safe zone has the same characteristics as the normal-rate zone, but has a lower pacing rate limit (e.g., 100 paces per minute). Transitions between monitoring zones are under program control in response to certain events or to telemetry commands. Digital keys may be used to protect against unintended transitions between zones.
1. Exemplary Pacemaker
The controller of the device is made up of a microprocessor 10 communicating with a memory 12 via a bidirectional data bus, where the memory 12 typically comprises a ROM (read-only memory) for program storage and a RAM (random-access memory) for data storage. The controller could be implemented by other types of logic circuitry (e.g., discrete components or programmable logic arrays) using a state machine type of design, but a microprocessor-based system is preferable. As used herein, the term circuitry should be taken to mean either the programming of a controller in the form of executable code stored in memory or other storage medium or to discrete logic circuitry configured to perform particular functions. The controller is capable of operating the device so as to deliver a number of different therapies in response to detected cardiac activity. A telemetry interface 80 is also provided for enabling the controller to communicate with an external programmer or other device via a wireless telemetry link.
The device shown in
The controller controls the overall operation of the device in accordance with programmed instructions stored in memory, including scheduling the delivery of paces via the pacing channels, interpreting sense signals received from the sensing channels, and implementing timers for defining escape intervals. The sensing circuitry of the pacemaker detects a chamber sense when an electrogram signal (i.e., a voltage sensed by an electrode representing cardiac electrical activity) generated by a particular channel exceeds a specified intrinsic detection threshold. Pacing algorithms used in particular pacing modes employ such senses to trigger or inhibit pacing. Both bradycardia and anti-tachycardia pacing modes may be implemented in code executed by the controller.
Bradycardia pacing modes refer to pacing algorithms which are used to pace the atria and/or ventricles in a manner that enforces a certain minimum heart rate or restores AV conduction. Bradycardia pacing modes are also used to deliver cardiac resynchronization pacing. Because of the risk of inducing an arrhythmia with asynchronous pacing, most pacemakers when delivering bradycardia pacing are programmed to operate synchronously in a so-called demand mode where sensed cardiac events occurring within a defined interval either trigger or inhibit a pacing pulse. Inhibited demand pacing modes utilize escape intervals to control pacing in accordance with sensed intrinsic activity. In an inhibited demand mode, a pacing pulse is delivered to a heart chamber during a cardiac cycle only after expiration of a defined escape interval during which no intrinsic beat by the chamber is detected. In a triggered mode, a sense occurring in one heart chamber triggers a pace to either the same or a different heart chamber. For example, in an atrial tracking mode, an atrial sense triggers an escape interval that results in a ventricular pace upon expiration.
The device of
2. Pacing Rate Monitoring System and Operation
In order to provide the pacemaker with protection against erroneous high-rate pacing and/or excessive delivery of pacing energy to the heart, the monitoring circuitry is designed to operate in two or more monitoring zones. One of the zones is the normal-rate zone for use during normal bradycardia pacing. When operating in the normal-rate zone, the monitoring circuitry is configured to set an error flag if the pacing rate exceeds a specified normal-rate limit value. As used herein, an error flag is any signal or indication to signify that the monitoring circuitry has detected an error condition. Another monitoring zone is the high-rate zone for use during ATP pacing, as well as certain test modes where bursts of high-rate pacing are employed. When operating in the high-rate zone, the monitoring circuitry is configured to set an error flag if either the pacing rate exceeds a specified high-rate limit value or if the pace count exceeds a specified count limit value. In the normal-rate zone, the monitoring circuitry may be configured to block the delivery of a scheduled pace that would exceed the normal-rate limit value and thereby causes the setting of an error flag. Similarly, in the high-rate zone, the monitoring circuitry may be configured to block delivery of a scheduled pace that would exceed the high-rate limit value or the count limit value and thereby causes the setting of an error flag. The monitoring circuitry in the normal-rate zone may be configured to permit, without setting an error flag, delivery of a pace during a specified grace interval after the preceding pace without regard to the specified rate limit value. The device may also incorporate circuitry to cause the monitoring circuitry to automatically operate in the normal-rate zone if pacing is being delivered in a bradycardia pacing mode and to operate in the high-rate zone if the pacing is being delivered in an anti-tachycardia pacing mode.
In one particular embodiment, where the device is configured to deliver ATP or other high-rate pacing to either the atria or ventricles, the monitoring circuitry is capable of simultaneously operating in either an atrial high-rate zone and a ventricular normal-rate zone or a ventricular high-rate zone and an atrial normal-rate zone. When operating in the atrial high-rate zone and ventricular normal-rate zone, the monitoring circuitry sets an error flag if either 1) the atrial pacing rate exceeds a specified atrial high-rate limit value or if the pace count exceeds the specified count limit value or 2) if the ventricular pacing rate exceeds the normal-rate limit value. Similarly, when operating in the ventricular high-rate zone and atrial normal-rate zone, the monitoring circuitry sets an error flag if either 1) the ventricular pacing rate exceeds a specified ventricular high-rate limit value or if the total pace count exceeds the specified count limit value or 2) the atrial pacing rate exceeds the normal-rate limit value. The device may also include circuitry to cause the monitoring circuitry to operate in the normal-rate zone if pacing is being delivered in a bradycardia pacing mode and to cause the monitoring circuitry to operate in the atrial high-rate zone and the ventricular normal-rate zone if the pacing is being delivered in an atrial anti-tachycardia pacing mode and in the ventricular high-rate zone and atrial normal-rate zone if the pacing is being delivered in a ventricular anti-tachycardia pacing mode. The monitoring circuitry may also be configured to block delivery of a scheduled pace that would exceed the normal-rate limit value, the atrial high-rate limit value, the ventricular high-rate limit value, or the specified count limit value and that results in the setting of an error flag.
In another particular embodiment, the pacing circuitry of the device is capable of delivering pacing pulses to first and second heart chambers in accordance with a programmed pacing mode, where the first and second heart chambers could be the right and left ventricles (or atria). The interval detection circuitry is configured to measure the interval between the times of a scheduled pace and a preceding delivered pace for both first chamber and second chamber paces and derive a first chamber pacing rate and a second chamber pacing rate therefrom. The counting circuitry is configured to count the number of first chamber and second chamber pacing pulses delivered over a specified time period and derive a total pace count therefrom (which may also include atrial paces). The monitoring circuitry is then configured to operate in either a normal-rate zone or a high-rate zone for both chambers.
In another embodiment, a fail-safe monitoring zone is provided in addition to normal-rate and high-rate zones, where the monitoring circuitry transitions to the fail-safe zone whenever an error flag is set is one of the other zones. The fail-safe zone has a specified fail-safe rate limit value, and the monitoring circuitry prevents scheduled paces from being delivered above the specified fail-safe rate limit value when operating in the fail-safe rate zone. The monitoring circuitry may be made further capable of operating in an unlimited-rate zone in which no rate limit values or count limit values are imposed that may be used for electrophysiological testing. The monitoring circuitry is caused to transition to the unlimited-rate zone upon receipt of an unlimited-rate zone command by the telemetry circuitry of the device and remains in the unlimited-rate zone for a specified test duration (e.g. 2 seconds). An error flag is set after the specified test duration expires at which point the monitoring circuitry reverts to the fail-safe zone. In a particular embodiment, the monitoring circuitry remains in the unlimited-rate zone for as long as an unlimited-rate zone command is continually received up to a specified clinical duration that is greater than the specified test duration (e.g., 30 seconds). For example, the unlimited-rate command may be issued from an external programmer when a clinician presses a particular key or button. As long as the key is depressed, an unlimited-rate zone command is continually transmitted so that the monitoring circuitry remains in the unlimited-rate zone until the either the key is released or the specified clinical duration expires.
Although the invention has been described in conjunction with the foregoing specific embodiments, many alternatives, variations, and modifications will be apparent to those of ordinary skill in the art. Such alternatives, variations, and modifications are intended to fall within the scope of the following appended claims.
This application is a divisional of and claims the benefit of priority under 35 U.S.C. §120 to U.S. patent application Ser. No. 11/316,682, now U.S. Pat. No. 7,826,897, filed on Dec. 22, 2005, which is hereby incorporated by reference herein in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
4969460 | Callaghan et al. | Nov 1990 | A |
5016630 | Moberg | May 1991 | A |
5190035 | Salo et al. | Mar 1993 | A |
5209228 | Cano et al. | May 1993 | A |
5237992 | Poore | Aug 1993 | A |
5282838 | Hauser et al. | Feb 1994 | A |
5284491 | Sutton et al. | Feb 1994 | A |
5309919 | Snell et al. | May 1994 | A |
5372607 | Stone et al. | Dec 1994 | A |
5374281 | Kristall et al. | Dec 1994 | A |
5487755 | Snell et al. | Jan 1996 | A |
5507786 | Morgan et al. | Apr 1996 | A |
5549654 | Powell | Aug 1996 | A |
5690689 | Sholder | Nov 1997 | A |
5702424 | Legay et al. | Dec 1997 | A |
5720771 | Snell | Feb 1998 | A |
5782886 | Kuiper et al. | Jul 1998 | A |
5861011 | Stoop | Jan 1999 | A |
5891175 | Walmsley et al. | Apr 1999 | A |
5948005 | Valikai et al. | Sep 1999 | A |
5968081 | Levine | Oct 1999 | A |
5974341 | Er et al. | Oct 1999 | A |
5991659 | de Vries et al. | Nov 1999 | A |
6070101 | Struble et al. | May 2000 | A |
6141586 | Mower | Oct 2000 | A |
6161042 | Hartley et al. | Dec 2000 | A |
6240313 | Esler | May 2001 | B1 |
6246909 | Ekwall | Jun 2001 | B1 |
6430439 | Wentkowski et al. | Aug 2002 | B1 |
6459928 | Mika et al. | Oct 2002 | B2 |
6477420 | Struble et al. | Nov 2002 | B1 |
6480742 | Stahmann et al. | Nov 2002 | B2 |
6665558 | Kalgren et al. | Dec 2003 | B2 |
6708061 | Salo et al. | Mar 2004 | B2 |
6748261 | Kroll et al. | Jun 2004 | B1 |
6904317 | Florio et al. | Jun 2005 | B2 |
6941167 | Stahmann et al. | Sep 2005 | B2 |
7194307 | Salo et al. | Mar 2007 | B2 |
20020082663 | Stahmann et al. | Jun 2002 | A1 |
20040082973 | Kim et al. | Apr 2004 | A1 |
20050137633 | Salo et al. | Jun 2005 | A1 |
20070150010 | Stubbs et al. | Jun 2007 | A1 |
Entry |
---|
“U.S. Appl. No. 10/744,952, Advisory Action mailed Jul. 24, 2006”, 3 pgs. |
“U.S. Appl. No. 10/744,952, Final Office Action mailed Apr. 18, 2006”, 9 pgs. |
“U.S. Appl. No. 10/744,952, Non Final Office Action mailed Jul. 8, 2005”, 9 pgs. |
“U.S. Appl. No. 10/744,952, Non Final Office Action mailed Nov. 23, 2005”, 8 pgs. |
“U.S. Appl. No. 10/744,952, Notice of Allowance mailed Nov. 9, 2006”, 4 pgs. |
“U.S. Appl. No. 10/744,952, Response filed Mar. 23, 2006 to Non Final Office Action mailed Nov. 23, 2005”, 7 pgs. |
“U.S. Appl. No. 10/744,952, Response filed Jul. 18, 2006 to Final Office Action mailed Apr. 18, 2006”, 9 pgs. |
“U.S. Appl. No. 10/744,952, Response filed Nov. 8, 2005 to Non Final Office Action mailed Jul. 8, 2005”, 11 pgs. |
“U.S. Appl. No. 11/316,682 Notice of Allowance mailed Jun. 30, 2010”, 6 pgs. |
“U.S. Appl. No. 11/316,682, Non-Final Office Action mailed Oct. 15, 2009”, 6 pgs. |
“U.S. Appl. No. 11/316,682, Response filed Jan. 15, 2010 to Non Final Office Action mailed Oct. 15, 2009”, 8 pgs. |
“U.S. Appl. No. 11/316,682, Response filed Jul. 24, 2009 to Restriction Requirement mailed Jun. 24, 2009”, 8 pgs. |
“U.S. Appl. No. 11/316,682, Restriction Requirement mailed Jun. 24, 2009”, 6 pgs. |
“U.S. Appl. No. 11/316,682, Notice of Allowance mailed Mar. 18, 2010”, 5 pgs. |
Number | Date | Country | |
---|---|---|---|
20110046689 A1 | Feb 2011 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 11316682 | Dec 2005 | US |
Child | 12916881 | US |